Session » Health Services Research – ACR/ARP Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1036

A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care

10:30AM-12:30PM: Abstract Number: 1043

A Prospective Study on Early Diagnosis of Inflammatory Rheumatic Diseases Using an Enhanced Online Questionnaire System (RhePort 1.3)

10:30AM-12:30PM: Abstract Number: 1041

A Theory of Change for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1044

Analysis of Rheumatic Patients’ Self – Reported Symptoms in Free Written Text Using Natural Language Processing

10:30AM-12:30PM: Abstract Number: 1056

Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1057

Barriers and Facilitators of Access to Physical Therapy: A Scoping Review

10:30AM-12:30PM: Abstract Number: 1052

Challenges and Opportunities in Post-Pandemic Remote Therapeutic Monitoring for Musculoskeletal Disease

10:30AM-12:30PM: Abstract Number: 1040

Clinic Personnel Perceptions Were Favorable for the Implementation of a Patient Decision-Aid for a Diverse Systemic Lupus Erythematosus Population: A Study in 15 U.S. Rheumatology Clinics

10:30AM-12:30PM: Abstract Number: 1034

Elucidating the Program Theory of a Successful Interdisciplinary Team-Based Model of Rheumatology Care: An Exploratory Case Study

10:30AM-12:30PM: Abstract Number: 1051

Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis

10:30AM-12:30PM: Abstract Number: 1042

Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study

10:30AM-12:30PM: Abstract Number: 1038

IMPACT (Impact of eMbedded Pharmacists in an Academic Center sTudy)

10:30AM-12:30PM: Abstract Number: 1035

Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors

10:30AM-12:30PM: Abstract Number: 1055

Impact of Provider Billing vs. Pharmacy Dispensation for Romosozumab Treatment Discontinuation Among U.S. Postmenopausal Women with Osteoporosis

10:30AM-12:30PM: Abstract Number: 1045

Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1047

Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1053

Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1037

Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review

10:30AM-12:30PM: Abstract Number: 1048

Self-Perception of Oral Health and Habits in Patients with Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1046

Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology

10:30AM-12:30PM: Abstract Number: 1050

The Cost-effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) for Patients with Knee Osteoarthritis and Obesity

10:30AM-12:30PM: Abstract Number: 1039

Through the LuCIN Lens: Defining Barriers and Forging Solutions for Lupus Clinical Trials in North America

10:30AM-12:30PM: Abstract Number: 1054

Utilization of Rehabilitation Services in Patients with Common Rheumatic Conditions: A Systematic Review

10:30AM-12:30PM: Abstract Number: 1049

Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].